Cardiology

More studies are planned testing the impact of finerenone.

Finerenone could be another option to SGLT2 inhibitors for this patient population.

Researchers present new data from the SUSTAIN 6 and PIONEER 6 trials during the virtual AHA 2020 conference.

AliveCor announced the US FDA has granted 510(k) clearance to Kardia AI V2 algorithm suite.

The rates of ALT normalization maintained in both arms of the 96 week study.

An analysis of data from a pair of major trials indicates use of semaglutide was associated with a reduction in MACE regardless of a patient's baseline triglyceride levels.

The lipid profile changes were not significant after 6 months, while the changes in the lipid profile are due to other factors and not the drugs.

The AI-based technology is expected to augment telehealth and remote services for a vast majority of cardiological cases.

An analysis of cardiovascular outcomes from FIDELIO-DKD suggest finerenone use was associated with a 14% reduction in negative cardiovascular outcomes.

Ongoing debates question whether or not lipid lowering in elderly patients offers similar clinical benefit as in younger patients.

In a recent column Gregory Weiss, MD, uses studies from AHA Scientific Sessions 2020 to compare the cost-effectiveness of antihyperglycemic agents for reducing cardiovascular events.

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

Lonafarnib was linked to improved mortality over a maximum of 11 years follow-up, according to supporting data.

Dr. Gregory Weiss reflects on data related to bariatric surgery and its subsequent impact on cardiovascular health.

An analysis of CDC data presented at AHA Scientific Sessions 2020 suggests rates of high blood pressure complications among pregnant women nearly doubled during a period lasting from 2008-2017.

An analysis from AHA 2020 suggests an HbA1c screening protocol doubled the proportion of patients with known dysglycemia when treating patients with ST-elevation myocardial infarction.

Gregory Weiss, MD, examines 4 studies presented at AHA Scientific Sessions 2020 comparing the cost-effectiveness of antidiabetic agents for reducing cardiovascular events.

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

George Bakris, MD, discusses a study he took part in from AHA 2020 examining the number of diabetic patients meeting the American Diabetes Association's criteria for prescribing an SGLT2 inhibitor.

In data from several studies presented at AHA 2020, investigators tout bempedoic acid in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia.

Deepak Bhatt, MD, MPH, offers his thoughts on the most important REDUCE-IT analyses released in 2020 and why he disagrees with the notion results of the STRENGTH trial somehow impact the use of icosapent ethyl in clinical settings.

Data from a pair of phase 3 trials detail the effects of sotagliflozin in patients with type 2 diabetes and other comorbidities, such as worsening heart failure and chronic kidney disease.

George Bakris, MD, offers further insight into the cardiovascular outcomes analysis of FIDELIO-DKD presented at AHA 2020.

Data from a phase 2 trial suggests evinacumab, in both subcutaneous and intravenous doses, were effective at lowering LDL-C in patients with refractory hypercholesterolemia.

Results of the EARLY-AF study suggest first-line ablation may be a better approach for patients with symptomatic atrial fibrillation than first-line antiarrhythmic drugs.